Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Process scale-up bridging study of a 9-valent recombinant HPV vaccine in Chinese women aged 18-26 years
CTR20240975Phase 3Completed
- Sponsor
- Xiamen Wantai Canghai Biotechnology Co., Ltd.
- Start
- Mar 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, anogenital warts, Cervical Cancer (CC), sponsored by Xiamen Wantai Canghai Biotechnology Co., Ltd.. Started Mar 2024; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionanogenital wartsCervical Cancer (CC)
Beyond the preview
Go deeper on CTR20240975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240975.